Literature DB >> 17727927

An update in neoadjuvant chemotherapy in cervical cancer.

Pieluigi Benedetti Panici1, Filippo Bellati, Maria Pastore, Natalina Manci, Angela Musella, Simona Pauselli, Michela Angelucci, Ludovico Muzii, Roberto Angioli.   

Abstract

More than two decades have passed since neoadjuvant chemotherapy has been introduced in the clinical practice. After several pilot studies, randomized trials and meta-analysis have confirmed the validity of this therapeutic strategy and in particular of neoadjuvant chemotherapy followed by radical surgery. Several open questions still remain unanswered and in particular no standard drug regiment is unanimously accepted. In this paper we describe how this treatment has evolved since its original introduction in the early eighties and describe possible drug regimens with their supporting evidence that can be adopted by physicians worldwide.

Entities:  

Mesh:

Year:  2007        PMID: 17727927     DOI: 10.1016/j.ygyno.2007.07.041

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

1.  Neoadjuvant chemotherapy followed by radical surgery as an alternative treatment to concurrent chemoradiotherapy for young premenopausal patients with FIGO stage IIB squamous cervical carcinoma.

Authors:  ShanShan Yang; Ying Gao; Jing Sun; Bairong Xia; TianBo Liu; HongXia Zhang; Qi Li; Min Xiao; YunYan Zhang
Journal:  Tumour Biol       Date:  2015-01-21

2.  [Neoadjuvant chemotherapy before radical hysterectomy in cervical cancer patients-response is not survival].

Authors:  Simone Marnitz; Nadine Gharbi
Journal:  Strahlenther Onkol       Date:  2018-09       Impact factor: 3.621

Review 3.  Monoclonal antibodies in gynecological cancer: a critical point of view.

Authors:  Filippo Bellati; Chiara Napoletano; Maria Luisa Gasparri; Valeria Visconti; Ilaria Grazia Zizzari; Ilary Ruscito; Jlenia Caccetta; Aurelia Rughetti; Pierluigi Benedetti-Panici; Marianna Nuti
Journal:  Clin Dev Immunol       Date:  2011-12-26

4.  Robotic single site radical hysterectomy plus pelvic lymphadenectomy in gynecological cancers.

Authors:  Enrico Vizza; Benito Chiofalo; Giuseppe Cutillo; Emanuela Mancini; Ermelinda Baiocco; Ashanti Zampa; Arabella Bufalo; Giacomo Corrado
Journal:  J Gynecol Oncol       Date:  2018-01       Impact factor: 4.401

5.  Squamous cell carcinoma antigen expression in tumor cells is associated with the chemosensitivity and survival of patients with cervical cancer receiving docetaxel-carboplatin-based neoadjuvant chemotherapy.

Authors:  Peng Chen; Liang Jiao; Dan-Bo Wang
Journal:  Oncol Lett       Date:  2017-01-02       Impact factor: 2.967

6.  A Comparison of Different Schemes of Neoadjuvant Chemotherapy Followed by Concurrent Chemotherapy and Radiotherapy for Locally Advanced Cervical Cancer: A Retrospective Study.

Authors:  Xue Tian; Feiyue Yang; Fenghu Li; Li Ran; Jianying Chang; Jiehui Li; Wei Hong; Lang Shan; Yanjun Du; Lili Hu; Fan Mei; Mingyuan He; Yongxia Li; Heran Wang; Kai Zuo; Bo Zhou; Shuying Chen; Wanli Mao
Journal:  Cancer Manag Res       Date:  2021-11-03       Impact factor: 3.989

7.  Chemoradiotherapy in combination with radical surgery is associated with better outcome in cervical cancer patients.

Authors:  Dan Zheng; Hua-Ping Mou; Peng Diao; Xiao-Ming Li; Chuan-Li Zhang; Jing Jiang; Jia-Lian Chen; Li-Shuai Wang; Qiu Wang; Guang-Yuan Zhou; Jie Chen; Chuan Lin; Zhi-Ping Yuan
Journal:  Oncotarget       Date:  2017-12-08

8.  Survival Nomograms after Curative Neoadjuvant Chemotherapy and Radical Surgery for Stage IB2-IIIB Cervical Cancer.

Authors:  Claudia Marchetti; Francesca De Felice; Anna Di Pinto; Alessia Romito; Angela Musella; Innocenza Palaia; Marco Monti; Vincenzo Tombolin; Ludovico Muzii; PierLuigi Benedetti Panici
Journal:  Cancer Res Treat       Date:  2017-07-19       Impact factor: 4.679

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.